Gilead (GILD $46.50) off 15% on Hep-C Clinical Data -Viral Relapse Seen
$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with GS-7977 Plus Ribavirin. Additional data will be forthcoming by the end of Q1 and Q2. Some analysts saw...
No Panic Just Take A Little Off:Caution- Update Rally 2/16
Market Reversal and a Light Sell-Off Technicals and a market reversal particularly a $20+ drop in AAPL gives us reason to take profits or hedge after a great start to 2012. The S&P is up 7% YTD, NAZ up 12% YTD, and the IBB biotech ETF up 16% YTD near its all time high. Some consolidation...
Rayno Life Science Portfolio Racks-Up More Gains: REGN, RGDX, SRLS
Who Does Not Know About the Bull Market in Biotech Stocks? The bull market in life science stocks gathered momentum today as the IBB rallied 2.34% (up 16.6% YTD) approaching its all time high of $122.45. At some point in time we need to have a correction as this rally is approaching 1999...
Response Genetics Raises $7.5M at $1.50 with New CEO
Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX) announced today that it has entered purchase agreements with private investors including current holders to raise more than $7.8M with placement...
Biopharma Market Re-Ignited by News and NASDAQ Strength
The IBB hit another new high today at $118.85 as the biotech bull market rolls on. Our index of biopharmaceutical stocks were up 4% at one time propelled by Medivation (MDVN $67.67) up 22% on favorable clinical news on its prostate cancer drug. A WSJ story helped move the stock. Medivation has...